Business
CORRECTING and REPLACING Cardio Diagnostics Holdings, Inc. Convenes Cardiovascular Care & Risk Roundtable at the 42nd Annual J.P. Morgan Healthcare Conference
The roundtable will bring together healthcare stakeholders to discuss operationalizing value-based care with novel risk-stratification strategies in the
About this update from Cardio Diagnostics Holdings Inc.
[{"type":"text","content":"\nThe roundtable will bring together healthcare stakeholders to discuss operationalizing value-based care with novel risk-stratification strategies in the cardiovascular disease space\n\n\n CHICAGO--(BUSINESS WIRE)--\n\nHeadline of release should read: Cardio Diagnostics Holdings, Inc. Convenes Cardiovascular Care & Risk Roundtable at the 42nd Annual J.P. Morgan Healthcare Conference (instead of Cardio Diagnostics Holdings, Inc’s Convenes Cardiovascular Care & Risk Roundtable at the 42nd Annual J.P. Morgan Healthcare Conference).\n\n\nThe updated release reads:\n\n\nCARDIO DIAGNOSTICS HOLDINGS, INC. CONVENES CARDIOVASCULAR CARE & RISK ROUNDTABLE AT THE 42ND ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE\n\n\nThe roundtable will bring together healthcare stakeholders to discuss operationalizing value-based care with novel risk-stratification strategies in the cardiovascular disease space\n\n\nCardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), a leader in artificial intelligence-driven precision cardiovascular medicine tests, today announced the company’s management will be attending the 42nd Annual J.P. Morgan Healthcare Conference, taking place from January 8 to 11, 2024, in San Francisco, CA.\n\n\nThe J.P. Morgan Healthcare Conference is the preeminent healthcare event in the country and regularly convenes America’s healthcare leaders to discuss the latest trends and innovations across the country. This year, novel medical technologies, company updates, and advancing care in an uncertain market environment will be among the leading discussions.\n\n\nIn response to the growing focus among healthcare leaders on mitigating risk, including financial risk, in an increasingly uncertain market environment, Cardio Diagnostics is pleased to announce it will be presenting a roundtable session titled “Operationalizing Value-Based Care in Shared Risk Contracts: A Novel Model for Heart Disease Risk Management.” Family Medicine Specialists’ President, Jason Bellucci MBA and Dr. Ross Hoffman, the Chief Medical Officer of Centene, are among the participants. According to the American Journal of Managed Care, 75% of provider organizations had at least one value-based care contract with a commercial health plan or a Medicare Advantage Plan. With the rise of value-based risk contracts, Cardio Diagnostics and its scalable and highly sensitive epigenetic-...